Sunday, November 24, 2024
name of Prensa Latina
Bandera inglesa
English Edition
Search
Close this search box.
name of Prensa Latina

NEWS

trials

Beijing, May 15 (Prensa Latina) China approved the emergent use of its sixth Covid-19 vaccine, amid the fight against a new outbreak of this disease, which has resulted in 10 cases so far.
Havana, Apr 26 (Prensa Latina) Abdala, Cuba's vaccine candidate against Covid-19, will conclude this week the administration of the third dose to all volunteers as part of the 3rd phase of clinical trials, it was announced on Monday.
Havana, Apr 20 (Prensa Latina) Studies of Cuba's Soberana Plus vaccine candidate continue in this capital in order to reinforce the protection and responsiveness of Covid-19 convalescing patients in the face of a possible reinfection.
Beirut, Apr 15 (Prensa Latina) Lebanese acting Minister of Health, Hamad Hassan, on Thursday showed interest in the clinical trials of Cuba's Covid-19 vaccines during a meeting with Cuban Ambassador to Beirut, Alexander Pellicer.
Havana, Apr 12 (Prensa Latina) A single dose of Cuba's vaccine candidate Soberana Plus can protect people against Covid-19 reinfection and improve their immune response to variants of the SARS-CoV-2 coronavirus, health authorities announced on Monday.
Tehran, Apr 8 (Prensa Latina) Iran and Cuba ratified their will to foster relations in the political, economic and health sectors, as a challenge to the United States' hostility, HispanTV reported on
Havana, Apr 5 (Prensa Latina) Over 62,000 people belonging to the controlled intervention trials with Cuba's vaccine candidates against Covid-19, Soberana 02 and Abdala, have received on Monday their first doses.
Havana, Apr 5 (Prensa Latina) Cuba's anti-Covid-19 vaccine candidates Soberana 02 and Abdala (CIGB-66) enter on Monday in the administration of the second dose in Phase III of clinical trials, each day closer to demonstrating their response capacity to fight SARS-Cov-2.
Havana, Mar 29 (Prensa Latina) Cuba might start the immunization of minors aged 5 to 18 against Covid-19 soon, after authorization was requested to the regulating medicines institution in the country, it was reported on Monday.